KYMR
Kymera Therapeutics, Inc.
+3.25 (+2.79%)119.58USD193K成交股數9.9B市值–本益比(近四季)94.7股價營收比+466.4%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 65.0M+194% | 34.4M+365% | 2.8M-26% | 11.5M-55% | 22.1M+115% | 7.4M+56% | 3.7M-77% | 25.7M+171% | 10.3M | 4.7M | 16.5M | 9.5M |
| 營業成本 | 65.0M | 34.4M | 2.8M | 11.5M | 22.1M | 7.4M | 3.7M | 25.7M | 10.3M | – | – | – |
| 毛利 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| 毛利率 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – |
| 研發費用 | 119M | 98.2M | 74.1M | 78.4M | 80.3M | 71.8M | 60.4M | 59.2M | 48.8M | 48.1M | 45.8M | 42.2M |
| 銷售管理費用 | 21.1M | 20.4M | 17.3M | 17.6M | 16.3M | 16.3M | 15.5M | 17.4M | 14.4M | 14.1M | 14.1M | 12.6M |
| 營業利益 | −75.6M+2% | −84.2M+4% | −92.5M+28% | −84.6M+66% | −74.4M+29% | −80.8M+40% | −72.1M+66% | −50.9M+12% | −57.8M | −57.5M | −43.4M | −45.3M |
| 營業利益率 | -116.3% | -244.9% | -3,347.4% | -736.8% | -336.8% | -1,092.2% | -1,927.9% | -198.5% | -562.2% | -1,216.3% | -262.7% | -478.8% |
| 稅後淨利 | −61.2M-7% | −69.2M-118% | −82.2M+32% | −76.6M+82% | −65.6M+35% | 377M-813% | −62.5M+61% | −42.1M+3% | −48.6M | −52.9M | −38.8M | −40.9M |
| 淨利率 | -94.2% | -201.5% | -2,973.0% | -667.6% | -296.7% | 5,098.2% | -1,670.3% | -164.0% | -472.0% | -1,118.2% | -235.0% | -432.4% |
| 稀釋 EPS | -0.62-24% | -0.71-20% | -0.94+15% | -0.95+64% | -0.82+19% | -0.89-1% | -0.82+22% | -0.58-17% | -0.69 | -0.90 | -0.67 | -0.70 |
| 稀釋股數 | 98.2M | 97.5M | 87.3M | 80.4M | 80.1M | 75.0M | 76.1M | 73.1M | 70.8M | 58.4M | 58.3M | 58.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 124M | 144M | 113M | 336M | 90.0M | 120M | 111M | 67.6M | 93.5M | 81.1M | 52.4M | 50.2M |
| 應收帳款 | 20.0M | – | – | 40.0M | – | 0 | 0 | 0 | 0 | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 1.6B | 1.7B | 1.1B | 1.1B | 918M | 978M | 1.0B | 826M | 868M | 552M | 582M | 614M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 136M | 129M | 156M | 160M | 132M | 142M | 142M | 141M | 157M | 157M | 147M | 152M |
| 股東權益 | 1.5B | 1.5B | 946M | 971M | 786M | 836M | 893M | 685M | 711M | 396M | 435M | 462M |
| 負債比 | 8.3% | 7.8% | 14.1% | 14.1% | 14.4% | 14.6% | 13.7% | 17.1% | 18.1% | 28.4% | 25.2% | 24.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −88.8M | – | – | −79.2M+100% | – | – | – | −39.6M | – | – | −44.0M |
| 資本支出 | – | 434K | – | – | 467K | – | – | – | 7.4M | – | – | 4.0M |
| 自由現金流 | – | −89.3M | – | – | −79.6M+69% | – | – | – | −47.0M | – | – | −48.0M |
| 折舊攤銷 | – | 2.0M | – | – | 2.0M | – | – | – | 1.5M | – | – | 879K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -259.8% | – | – | -360.3% | – | – | – | -456.8% | – | – | -506.8% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 39.2M | -16.7% | 311M | 794.0% | -3.69 | −234M |
| FY2024 | 47.1M | -40.1% | 224M | 475.6% | -2.98 | −207M |
| FY2023 | 78.6M | +67.8% | 147M | 187.0% | -2.52 | −137M |
| FY2022 | 46.8M | -35.7% | 155M | 330.6% | -2.87 | −156M |
| FY2021 | 72.8M | +114.0% | 100M | 137.6% | -2.09 | −131M |
| FY2020 | 34.0M | +1060.0% | −45.6M | -134.0% | -3.15 | 79.0M |
| FY2019 | 2.9M | – | −41.2M | -1,405.8% | -24.28 | 17.4M |